Real-world outcomes with durvalumab (durva) after chemoradiotherapy (CRT) in patients with unresectable stage III NSCLC (SPOTLIGHT)

被引：3
|
作者：
Mooradian, M. [1 ,2 ]
Allen, A. [3 ]
Cai, L. [3 ]
Xiao, Y. [3 ]
Chander, P. [3 ]
机构：
[1] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] AstraZeneca, Gaithersburg, MD USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.02.143
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
116P
引用
收藏
页码：S86 / S86
页数：1
相关论文
共 50 条
  • [1] SPOTLIGHT real-world study: Outcomes with or without consolidation durvalumab (D) after chemoradiotherapy (CRT) in patients with unresectable stage III NSCLC
    Whitaker, R. M.
    Cai, L.
    Wang, A.
    Qiao, Y.
    Chander, P.
    Mooradian, M.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S111 - S111
  • [2] SPOTLIGHT real-world study: Patient characteristics and treatment patterns in patients with unresectable stage III NSCLC receiving durvalumab after chemoradiotherapy (CRT)
    Mooradian, M. J.
    Allen, A.
    Cai, L.
    Xiao, Y.
    Chander, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S1417 - S1418
  • [3] Real-World Outcomes with Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFRMutated NSCLC (PACIFIC-R)
    Peters, S.
    Christoph, D. C.
    Field, J. K.
    Fietkau, R.
    Filippi, A. R.
    Garassino, M.
    Garrido, P.
    McDonald, F.
    Mornex, F.
    Markman, B.
    Solomon, B. J.
    Anand, S.
    Chander, P.
    Qiao, Y.
    Girard, N.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S83 - S83
  • [4] Durvalumab after Chemoradiotherapy (CRT) in Unresectable Stage III NSCLC. Comparative Study of Two Cohorts in the Real-World Setting
    Tavara, B.
    Rojas, M.
    Rodriguez, Z.
    Garrido, M. L.
    Lopez, L.
    Medina, S.
    Ponte, C.
    Lopez, A.
    Sanchez, E.
    Pedraza, M.
    Vinals, P.
    Lopez, M.
    Alonso, D.
    Rodriguez, A.
    Castanon, C.
    Davila, E.
    De Sande, L. M.
    Nieto, B.
    Vallejo Pascual, M. E.
    Rodriguez, J. D. L. R.
    Garcia Palomo, A.
    Diz Tain, P.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S283 - S284
  • [5] Durvalumab Consolidation After Chemoradiotherapy in Elderly Patients With Unresectable Stage III NSCLC: A Real-World Multicenter Study
    Park, Ji Eun
    Hong, Kyung Soo
    Choi, Sun Ha
    Lee, Shin Yup
    Shin, Kyeong-Cheol
    Jang, Jong Geol
    Kwon, Yong Shik
    Park, Sun Hyo
    Choi, Keum-Ju
    Jung, Chi Young
    Eom, Jung Seop
    Kim, Saerom
    Seol, Hee Yun
    Kim, Jehun
    Kim, Insu
    Park, Jin Han
    Kim, Tae Hoon
    Ahn, June Hong
    CLINICAL LUNG CANCER, 2024, 25 (04) : 354 - 364
  • [6] PACIFIC-R: Real-world characteristics of unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
    McDonald, F.
    Mornex, F.
    Garassino, M. C.
    Filippi, A. R.
    Christoph, D.
    Haakensen, V. D.
    Agbarya, A.
    Van den Heuvel, M.
    Vercauter, P.
    Chouaid, C.
    Pichon, E.
    Siva, S.
    Steinbusch, L.
    Peretz, I.
    Solomon, B.
    Decoster, L.
    Sawyer, W.
    Allen, A.
    Licour, M.
    Girard, N.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S738 - S739
  • [7] First Real-World Data on Unresectable Stage III NSCLC Patients Treated with Durvalumab after Chemoradiotherapy in Asia Area
    Kuo, C.
    Yang, T. Y.
    Wang, C. C.
    Hua, C. C.
    Hsia, T. C.
    Chiang, C. L.
    Ko, J. C.
    Tsai, C. L.
    Su, P. L.
    Su, J.
    Ho, C. C.
    Chang, G. C.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S265 - S266
  • [8] Durvalumab (durva) after sequential chemoradiotherapy (CRT) in patients (pts) with unresectable stage III NSCLC: Final analysis from PACIFIC-6
    Garassino, M. C.
    Mazieres, J.
    Reck, M.
    Chouaid, C.
    Bischoff, H.
    Reinmuth, N.
    Cove-Smith, L. S.
    Mansy, T.
    Cortinovis, D. L.
    Migliorino, M. R.
    Delmonte, A.
    Sanchez, J. Garcia
    Velarde, L. E. Chara
    Caro, R. Bernabe
    Paz-Ares, L.
    Chander, P.
    Perez, I. Diaz
    Foroutanpour, K.
    Faivre-Finn, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S1301 - S1302
  • [9] The S-REAL study: Spanish real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy
    Rueda, Ana Gomez
    Taus, Alvaro
    Alvarez, Rosa Alvarez
    Bernabe-Caro, Reyes
    Chara, Luis
    Lopez-Brea, Marta
    Vila, Laia
    Gonzalez, Maria Angeles Sala
    Aldagalan, Anabel del Barrio Diaz
    Herrera, Beatriz Esteban
    Castro, Rafael Lopez
    Cabellos, Ruth Alvarez
    Domenech, Marta
    Falagan, Sandra
    Vega, Alberto Moreno
    Aguado, Carlos
    Barba, Andres
    Urena, Maria Teresa Delgado
    Isla, Dolores
    Hernandez, Lorena Bellido
    Perez, Jose Luis Firvida
    Juan-Vidal, Oscar
    Massuti, Bartomeu
    Mielgo-Rubio, Xabier
    Ortega, Ana Laura
    Catot, Silvia
    Domine, Manuel
    Escoin-Perez, Corina
    Navalon, Francisco Garcia
    Gil-Bazo, Ignacio
    Munoz, Silvia
    Rodriguez-Abreu, Delvys
    Roldan, Rosa Maria Villatoro
    Curbera, Guillermo Alonso-Jaudenes
    Leon-Mateos, Luis
    Padilla, Airam
    Lario, Alfredo Paredes
    Sanchez-Torres, Jose Miguel
    Garrido, Pilar
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (09): : 2205 - 2216
  • [10] Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR
    Park, Cheol-Kyu
    Oh, Hyung-Joo
    Kim, Young-Chul
    Kim, Yong-Hyub
    Ahn, Sung-Ja
    Jeong, Won Gi
    Lee, Jeong Yeop
    Lee, Jae Cheol
    Choi, Chang Min
    Ji, Wonjun
    Song, Si Yeol
    Choi, Juwhan
    Lee, Sung Yong
    Kim, Hakyoung
    Lee, Shin Yup
    Park, Jongmoo
    Yoon, Seong Hoon
    Joo, Ji Hyeon
    Oh, In-Jae
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (08) : 1042 - 1054
12345